Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... GlassesOff (OTCBB: GLSO), a visual neuroscience technology company ... system, announced today a partnership with eight-time All-Star, ... to develop a new mobile app designed for professional and ... performance. Vision is the inception of every move ... or blocking a pass. The critical impact vision speed has ...
(Date:8/26/2015)... ... August 26, 2015 , ... MediVet Biologics, a leader ... laboratory is to open in Manhattan, Kansas in early October, 2015. The location ... of research and development through collaboration with researchers from Kansas State University’s College ...
(Date:8/26/2015)... Aug. 26, 2015  Platform therapeutic company Symic ... received a $1.5M Phase II SBIR grant from ... develop its therapeutic agent to reduce arteriovenous fistula ... end stage renal disease (ESRD) patients undergoing hemodialysis. ... of Diabetes and Digestive and Kidney Diseases (NIDDK), ...
(Date:8/26/2015)... Florida , August 26, 2015 ... the biggest factors fueling the optimism in biotech,s ... M&A,s, collaborations and life sciences advancements.  Active biotechnology ... are Pressure BioSciences, Inc. (OTCQB: PBIO), Sequenom, Inc. ... SRPT ), Raptor Pharmaceutical Corp. (NASDAQ: ...
Breaking Biology Technology:Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 2Eight-Time All-Star Chris Paul and GlassesOff Partner to Develop Innovative Mobile App Designed to Improve On-Court Performance 3MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 2MediVet Biologics Animal Health Secures Additional Laboratory Facility in Manhattan, Kansas 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 2New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 3New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 4New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 5New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 6New Collaborations & Mergers For Research of Molecular Biomarkers in Human Diseases & Clinical Trials for Cancer Therapies Fueling Growth in Multi-Billion Dollar Life Sciences Market 7
... Italy, November 10 Health-Robotics today,announced that ... Automation since,1971, has selected Health Robotics, CytoCare(TM) ... by TOSHO,s engineering and management,teams, and by ... process included multiple visits to Health Robotics, ...
... Delivery Technology and own Pipeline ... ... 10 Critical,Pharmaceuticals, the speciality pharmaceuticals company, today announced,that it ... on the company,s success in developing its unique,CriticalMix delivery technology ...
... and research group Plasma & Materials Processing (PMP) of ... awarded the Leverhulme Technology Transfer Award 2008. They receive ... for the research group) for their successful transfer of ... Hoex,s Ph.D. research was rewarded with the SolarWorld Junior ...
Cached Biology Technology:Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc. 2Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc. 3Health Robotics Announces Strategic Partnership in Japan for its CytoCare(TM) Robot with TOSHO Inc. 4Critical Pharmaceuticals Raise GBP650K 2Critical Pharmaceuticals Raise GBP650K 3TU/e awarded for knowledge transfer to solar energy industry 2
(Date:8/5/2015)... 2015 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends and ... recognition is forecast to reach US$ 2,671.8 Mn by ... surveillance systems by civil and government agencies. This is ... terrorist activities across the globe that would elevate the ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
Breaking Biology News(10 mins):Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 2Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 3Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 4Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 5Facial Recognition Market Expected to Reach US$ 2.67 Bn by 2022, at a CAGR of 9.5% From 2015 - 2022: Transparency Market Research 6La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3
... 28, 2012 In 2012 Wiley-Blackwell, the Scientific, Technical, ... Sons, Inc., will begin publishing 44 titles new to ... journals published in collaboration with societies or other organizations. ... over the course of 2012 include Advanced Healthcare ...
... The bacterium Mycoplasma pneumoniae , which causes ... the most of limited resources. By measuring all the ... Biology Laboratory (EMBL) in Heidelberg, Germany, and collaborators, have ... a mechanic can fine-tune a car after it has ...
... SANTA CLARA, Calif., and SHENZHEN, China, Feb. ... and BGI today announced a collaborative effort to ... The methodologies will assist scientists pursuing disease and ... is to create a next-generation super exome, using ...
Cached Biology News:Wiley-Blackwell adds 44 titles to journal publishing program in 2012 2Making the most of what you have 2Agilent Technologies and BGI to collaborate on next-generation super array 2
... DNA Ligase catalyzes the formation of a ... termini in nicked duplex DNA molecules or ... a complementary strand at 45 - 65?. ... at much higher temperatures than conventional DNA ...
MAb to Mouse MHC Class I H-2Kd...
hnRNP U (H-94)...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
Biology Products: